BioRestorative Therapies Inc

BRTX

Add to Watchlist

0.192USD

+0.003+1.75%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

BioRestorative Therapies Inc's Score

Industry at a Glance

Industry Ranking

175 / 382

Overall Ranking

318 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

BioRestorative Therapies Inc Highlights

StrengthsRisks

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 146.71% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 359.70K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 359.70K.

Overvalued

The company’s latest PE is -0.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.24M shares, decreasing 15.25% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.30.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

8.000

Target Price

+4135.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of BioRestorative Therapies Inc is 5.51, ranking 344 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 23.17K, representing a year-over-year decrease of 7.32%, while its net profit experienced a year-over-year decrease of 59.65%.

Score

Industry at a Glance

Previous score

5.51

Change

0



Financials

4.65

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.35

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of BioRestorative Therapies Inc is 7.70, ranking 86 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.18, which is -15222.13% below the recent high of 27.27 and -1309.65% above the recent low of -2.54.

Score

Industry at a Glance

Previous score

7.70

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 175/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of BioRestorative Therapies Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 18.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of BioRestorative Therapies Inc is 4.45, ranking 344 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.25 and the support level at 0.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.41

Change

0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of BioRestorative Therapies Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.89%, representing a quarter-over-quarter decrease of 54.77%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Alta Partners L.L.C

1.79M

--

Broadrick (Dale)

923.90K

--

Auctus Fund Management, L.L.C.

817.79K

+1.69%

Alstodt (Lance)

187.50K

--

Silva (Francisco)

183.52K

+2.17%

Geode Capital Management, L.L.C.

57.85K

+4.68%

DRW Securities, LLC

46.66K

--

Wealth Alliance

40.00K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioRestorative Therapies Inc is 2.08, ranking 243 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.17. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

BioRestorative Therapies Inc

BRTX

5.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment